Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Optimization of restraint system parameters for reclined drivers in frontal collisions based on finite element modeling.

Traffic injury prevention·2026
Same author

Interpretable stacking model integrating intra-/peritumoral CT-radiomics and serum biomarkers for predicting microvascular invasion in HCC: a dual-center retrospective study.

BMC gastroenterology·2026
Same author

Remnant cholesterol and body mass index jointly associate with cardiometabolic Multimorbidity with mediation analysis in CHARLS a prospective cohort study.

Scientific reports·2025
Same author

Association between systemic immune inflammation index and mortality risks in type 2 diabetes based on NHANES.

Medicine·2025
Same author

Analysis of factors influencing the severity of crashes between new-energy vehicles and pedestrians based on theoretical and data-driven models.

Traffic injury prevention·2025
Same author

Causation analysis of serious road traffic accidents in Sichuan Province of China based on a hybrid HFACS-CN model.

Traffic injury prevention·2025

相关实验视频

Updated: Jun 23, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

在急性冠状动脉综合征的穿皮冠状动脉干预期间,用abciximab,tiRofiban和eptifibatide进行血小板抑制的随机比较:COMPARE试验.

Wayne B Batchelor1, Thaddeus R Tolleson, Yao Huang

  • 1Tallahassee Heart and Vascular Institute, Tallahassee Memorial Healthcare, Tallahassee, Fla 32308, USA. batch002@earthlink.net

Circulation
|September 18, 2002
PubMed
概括
此摘要是机器生成的。

在穿皮冠状动脉干预过程中,eptifibatide在糖蛋白IIb/IIIa抑制剂中表现出最一致的抗血小板聚合效应. 这项研究在急性冠状动脉综合征患者中比较了abciximab,eptifibatide和tirofiban.

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

相关实验视频

Last Updated: Jun 23, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

科学领域:

  • 心血管医学 心血管医学
  • 药理学 药理学是指药理学的学科.
  • 干预心脏病学 干预心脏病学

背景情况:

  • 血小板糖蛋白IIb/IIIa受体对抗剂在急性冠状动脉综合征 (ACS) 的皮肤通冠状动脉干预 (PCI) 中至关重要.
  • 这些药物在PCI期间和之后的比较抗聚合作用尚未得到充分证实.

研究的目的:

  • 为了比较abciximab,eptifibatide和tirofiban的相对抗聚合作用.
  • 在接受PCI的ACS患者中评估这些影响.

主要方法:

  • 在接受PCI的70名ACS患者的随机试验中.
  • 在标准剂量中使用abciximab,eptifibatide或tirofiban.
  • 在药物开始后的不同时间点使用度计聚合计测量血小板聚合 (PA) 的测量.

主要成果:

  • 与abciximab和eptifibatide相比,tirofiban在早期显示出明显较少的PA抑制.
  • 在长时间输液时,abciximab表现出可变的抗聚合作用.
  • 在早期和晚期,eptifibatide表现出最一致的PA抑制作用.

结论:

  • 糖蛋白IIb/IIIa抑制剂具有不同的药理动力学特征.
  • 这些差异可能会影响它们在接受PCI的ACS患者的临床疗效.